Author

Pascale Tomasini

Observed names: P. Tomasini, P.T. Tomasini, Tomasini, P., Tomasini, Pascale

Observed institutions: Centre National de la Recherche Scientifique, University Health Network, Inserm, University of Toronto, Aix-Marseille Université, Princess Margaret Cancer Centre, Centre Hospitalier Universitaire de Bordeaux, Assistance Publique Hôpitaux de Marseille, Centre Georges François Leclerc, Hôpital Européen Georges-Pompidou, Centre Inria d'Université Côte d'Azur, Hôpital Nord, Centre Oscar Lambret, Centre de Recherche en Cancérologie de Marseille, Hôpital de la Timone, COMPO: Méthodes computationnelles pour la prise en charge thérapeutique en oncologie, Université Henri Poincaré, Université de la Méditerranée Aix-Marseille II, Guangzhou Medical University

ORCID: 0000-0002-6474-5912

Observed ORCID: 0000-0002-6474-5912

OpenAlex ID: A5058623156

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

2023 · A. Passaro, J. Wang, et al. · Annals of Oncology · 446

PDF

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

2017 · Myriam Delaunay, Jacques Cadranel, et al. · European Respiratory Journal · 414

PDF

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

2013 · M. Beau-Faller, N. Prim, et al. · Annals of Oncology · 324

PDF

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

2019 · Arnaud Jeanson, Pascale Tomasini, et al. · Journal of Thoracic Oncology · 231

PDF

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

2017 · Catherine Labbé, Michael Cabanero, et al. · Lung Cancer · 229

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 · Alexander Drilon, Vivek Subbiah, et al. · Journal of Clinical Oncology · 214

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

2018 · Mathieu Grangeon, Pascale Tomasini, et al. · Clinical Lung Cancer · 203

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

2024 · D. Ross Camidge, Jair Bar, et al. · Journal of Clinical Oncology · 180

Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

2023 · Grace K. Dy, Ramaswamy Govindan, et al. · Journal of Clinical Oncology · 162

PDF

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

2016 · Pascale Tomasini, Preet Walia, et al. · The Oncologist · 132

PDF

The clinical utility of tumor mutational burden in non-small cell lung cancer

2018 · Laurent Greillier, Pascale Tomasini, et al. · Translational Lung Cancer Research · 122

PDF

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

2024 · E. Felip, B.C. Cho, et al. · Annals of Oncology · 103

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer

2023 · François Ghiringhelli, Frederic Bibeau, et al. · EBioMedicine · 90

PDF

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

2016 · Pascale Tomasini, Cindy Serdjebi, et al. · International Journal of Molecular Sciences · 71

PDF

Ipilimumab: its potential in non-small cell lung cancer

2011 · Pascale Tomasini, Nataliya Khobta, et al. · Therapeutic Advances in Medical Oncology · 71

PDF

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

2022 · D. Ross Camidge, Jair Bar, et al. · Journal of Clinical Oncology · 70

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

2016 · Pascale Tomasini, Fabrice Barlesi, et al. · Therapeutic Advances in Medical Oncology · 66

PDF

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial

2025 · Fabrice Barlesi, Wenxiu Yao, et al. · The Lancet · 63

Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001

2024 · Lori J. Wirth, Marcia S. Brose, et al. · Journal of Clinical Oncology · 57

PDF

Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer

2017 · Mark K. Doherty, Grzegorz J. Korpanty, et al. · Radiotherapy and Oncology · 55

Feasibility and diagnostic accuracy of the Patient‐Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care

2016 · Yvonne W. Leung, Catherine Brown, et al. · Cancer · 54

PDF

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

2025 · Ferdinandos Skoulidis, Bob T. Li, et al. · Nature Medicine · 48

PDF

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

2023 · Ross A. Soo, Jean-François Martini, et al. · Journal of Thoracic Oncology · 48

PDF

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases

2019 · Pascale Tomasini, Julie Egea, et al. · Therapeutic Advances in Respiratory Disease · 48

Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib

2025 · H. Horinouchi, B.C. Cho, et al. · Annals of Oncology · 47

PDF

Works count: 353

Citation count: 5,075

H-index: 34

I10-index: 79